Treatment of Congenital Hemophilia A and B
Publication Date: June 19, 2024
Key Points
Key Points
- Hemophilia is a congenital X-linked bleeding disorder that affects an estimated 1,125,000 individuals worldwide, 80% of whom have hemophilia A.
- Individuals with severe (and some moderate) forms of hemophilia not treated with prophylaxis may experience spontaneous bleeding, of which the most frequent are joint and muscle bleeding.
- Prophylaxis rather than episodic treatment is strongly recommended for severe and moderately-severe hemophilia A and B.
Treatment
Treatment
...A Without Inhibitors...
...individuals with severe and moderat...
...iduals with severe and moderately-severe hemophi...
In individuals with severe and moderately...
...mited settings in which the use of standard-...
...viously untreated individuals with severe hem...
...viduals with severe and moderately-severe...
...lia A With Inhibitors...
...n individuals with severe hemophilia A with inh...
...with severe hemophilia A with inhib...
...with severe hemophilia A with high-responding inhi...
...uals with severe hemophilia A with inhi...
...ls with severe hemophilia A with inhibit...
...lia B Without Inhibitors...
...dividuals with severe and moderatel...
...dividuals with severe and moderately-severe hemo...